• Powered by Crown Equity Holdings Inc.
      • crown-logo

        Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Post on CRWE World Login
logo Fairfield, UNITED STATES
header-img
  • Home
  • News
  • World
      • World News
      • Español
  • Politics
      • U.S. Legislators
      • Political News
  • Sports
  • Business
      • Markets
      • Hottest Stocks Today
      • CRWEWorld Stocks
      • Blockchain
      • Regulatory
      • Accounting
      • Fundraising Campaigns
      • IPOs
      • Money
      • Career
  • Tech
      • Tech
      • Science
  • Living
      • Arts & Entertainment
      • Family
      • Food
      • Pets
      • Seniors
      • Fashion/Fitness
      • Home & Garden
  • Health
      • Health
      • Pharma & Biotech
  • Opinion
      • Finance
      • Law
      • Healthcare
      • Cannabidiol (CBD)
      • Fashion
      • Podcasts
      • Tech
      • Music
  • Travel
  • Local
      • News
      • Trending Now
      • Real Estate
      • Coupons & Deals
      • Business Directory
  • Jobs
  • More
      • Business 2 Business
      • Press Releases
      • Press Releases Pricing
      • News from GlobeNewswire
      • News from PR Newswire
      • News from Business Wire
      • News from Accesswire
      • Video Channels
      • Beauty
      • Business
      • Comedy
      • Entertainment
      • Fashion
      • Featured
      • Health
      • Instructional
      • News
      • Politics
      • Sports
      • Technology
      • Entertainment
      • Horoscope
      • Sudoku
      • Crossword
      • Games
      • Chat
      • Affiliate | How It Works
      • Join CRWE WORLD Affiliate Program
      • CRWE WORLD Advertising Services Rate
      • Crown Equity Holdings' Overview
      • CRWEWorld Real-Time Global Visitors
      • Content Delivery Solution
        • Contact Us
  • More

Change City


-- OR --
load
load
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png
  • Home
  • Articles
  • News Provided by PR Newswire
21ьз╕ Cweather-icon
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png

Cantargia Announces Pre-clinical Results Showing Positive Effects of CAN04 Combined With Approved Cancer Therapies

News Provided by PR Newswire2018-06-26
22 Views

Cantargia Announces Pre-clinical Results Showing Positive Effects of CAN04 Combined With Approved Cancer Therapies

 
[26-June-2018]
 

STOCKHOLM, June 26, 2018 /PRNewswire/ --Cantargia AB today announces pre-clinical results from a study combining the antibody CAN04 (nidanilimab) and chemotherapy. In in vivo based models of cancer, CAN04 was safely combined with the tested chemotherapies. The strongest result was obtained by combining CAN04 with cisplatin, demonstrating both a significantly improved therapeutic effect as well as a clear CAN04-related reduction of cisplatin side effects.

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead drug candidate CAN04 is in a phase I/IIa clinical trial (CANFOUR), where monotherapy dose escalation is initially investigated followed by monotherapy as well as combination therapy cohorts in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer. Cisplatin is part of standard therapy regimes in lung cancer and other cancers such as head and neck cancer, ovarian cancer and bladder cancer. In tumor bearing mice, combining CAN04 and cisplatin led to antitumor effects stronger than those observed using each individual agent. In addition, CAN04 counteracted cisplatin induced toxicity in these mice. Further investigations are ongoing and the results are planned to be presented at a scientific conference during 2018. Following results from independent groups showing that interleukin-1 blockade counteracts gemcitabine resistance during cancer treatment, studies combining CAN04 and gemcitabine support the combination. Gemcitabine is approved for treatment of NSCLC, pancreatic cancer and breast cancer.

"These data are very promising for the CAN04 development. It shows that CAN04 can be combined safely with chemotherapy to improve antitumor effects. Of additional importance is the finding that CAN04 reduced cisplatin toxicity in an in vivo cancer model", Göran Forsberg, Cantargia's CEO says.

For further information, please contact

Göran Forsberg, CEO

Telephone: +46(0)46-275-62-60

E-mail: goran.forsberg@cantargia.com

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CET on 26 June 2018.

About Cantargia

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company's main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia's second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/cantargia-ab/r/cantargia-announces-pre-clinical-results-showing-positive-effects-of-can04-combined-with-approved-ca,c2557938

The following files are available for download:

http://mb.cision.com/Main/7470/2557938/866786.pdf

PDF


Company Codes: ISIN:SE0006371126, Stockholm:CANTA


© 2018 PR Newswire. All Rights Reserved.

#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.


Tesla (Nasdaq: TSLA) Announces Date for First Quarter 2021 Financial Results and Webcast



/assets/img/cw-stocks.png

/assets/img/wysh-jewels.png

/assets/img/hjli.png

/assets/img/Mars-Parachute-2.png

/assets/img/crweworld-podcast.jpg
Sponsored
Also read
MP William Amos speaks out: Leaked naked photo sends message 'anything goes' in politics
Iran nuclear: State TV names suspect in Natanz attack
Statement from CNH Industrial
Gold price rises 1.63% to Rs 47,350/10 gm; Ideas for investors, technicals and key events to watch out for
IPL 2021 | MI vs SRH LIVE Score: Check ball-by-ball updates, full scorecard
China’s Ant explores ways for Jack Ma to exit as Beijing piles pressure
Cotton tumbles 2.15% to Rs 21,380 per bale this week; outlook bullish
Kiren Rijiju tests positive for COVID-19, says he is feeling #39;fit and fine#39;


Post on CRWE WorldSign Up for Free E-mail Updates
  • Real Estate Eagle Firm, Real Estate
  • Hancock Jaffe Laboratories, Nasdaq:HJLI, HJLI
Signup for free email updates
/assets/img/wall-street-rect2.png
/assets/img/wall-street-sq.png



Join with us
Live Traffic Feed
About CrweWorld
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Finance Disclaimer
  • Jobs
Subscribe for newsletter
3+2
Contact Info
  • contact@crweworld.com

  • P: (702) 683-8946

  • P: (702) 810-0178

  • 11226 Pentland Downs St, Las Vegas, NV 89141

Tweets by CrweWorld
Tweets by @CrweWorld
  • © 2021 crweworld.com
ad1

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

ad3

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

ad5

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

Advertisements

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

CRWE WORLD Advertising Services RateJoin CRWE WORLD Affiliate Program